Enanta Pharmaceuticals, Inc.(ENTA)

$13.43—

Chart

Enanta Pharmaceuticals, Inc.(ENTA)

NASDAQ

$13.43—

Chart Studio

ENTA(ENTA)

ENTA

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.64

Nov 16, 2026

Revenue Estimate

$16M

Analyst Sentiment

Wall St. Consensus

Buy

16 analysts·Moderate coverage

Score

14 Buy (88%)0 Hold (0%)2 Sell (12%)

Rating Breakdown

Strong Buy

00%

Buy

1488%

Hold

00%

Sell

213%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$20.00

+48.9%

Consensus

$20.00

+48.9%

Bull

$20.00

+48.9%

12-Month Target Range16 analysts

$20.00$20.00$20.00

Current $13.43Consensus

Current Price

$13.43

Upside to Consensus

$6.57

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-2.32%

EPS—

FY2028

Rev+12.16%

EPS—

FY2029

Rev+32.67%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$67M	$66M	$74M	$98M	$154M
Low	$67M	$65M	$37M	$81M	$128M
High	$68M	$66M	$126M	$117M	$184M
EBITDA Avg	$-67M	$-66M	$-74M	$-98M	$-154M
Low	$-68M	$-66M	$-126M	$-117M	$-184M
High	$-67M	$-65M	$-37M	$-81M	$-128M
EBIT Avg	$-67M	$-66M	$-74M	$-98M	$-154M
Low	$-68M	$-66M	$-126M	$-117M	$-184M
High	$-67M	$-65M	$-37M	$-81M	$-128M
Net Income Avg	$-59M	$-57M	$-66M	$-43M	$-32M
Low	$-60M	$-58M	$-77M	$-54M	$-41M
High	$-38M	$-30M	$-26M	$-33M	$-25M
EPS Avg	$-2.30	$-2.07	$-2.12	$-2.00	$-1.52
Low	$-2.80	$-2.73	$-3.60	$-2.51	$-1.91
High	$-1.78	$-1.41	$-1.21	$-1.56	$-1.18
Analysts (Rev / EPS)	3 / 2	4 / 4	3 / 3	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027
Revenue Avg	$17M	$17M	$15M	$16M	$15M
Low	$16M	$16M	$14M	$15M	$14M
High	$17M	$18M	$16M	$17M	$16M
EBITDA Avg	$-17M	$-17M	$-15M	$-16M	$-15M
Low	$-17M	$-18M	$-16M	$-17M	$-16M
High	$-16M	$-16M	$-14M	$-15M	$-14M
EBIT Avg	$-17M	$-17M	$-15M	$-16M	$-15M
Low	$-17M	$-18M	$-16M	$-17M	$-16M
High	$-16M	$-16M	$-14M	$-15M	$-14M
Net Income Avg	$-19M	$-11M	$-13M	$-13M	$-14M
Low	$-27M	$-12M	$-14M	$-14M	$-16M
High	$-10M	$-10M	$-12M	$-12M	$-13M
EPS Avg	$-0.64	$-0.36	$-0.43	$-0.43	$-0.49
Low	$-0.94	$-0.41	$-0.48	$-0.48	$-0.54
High	$-0.35	$-0.34	$-0.40	$-0.40	$-0.45
Analysts (Rev / EPS)	2 / 2	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Jun 23, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)

Target:$20.00

+49.6%from $13.37

Oct 1, 2025Jefferies

Enanta upgraded to Buy from Hold at Jefferies

Target:$20.00

+83.7%from $10.88

Jun 3, 2025JMP Securities

Enanta price target raised to $24 from $23 at Citizens JMP

Target:$24.00

+233.8%from $7.19

Dec 9, 2022H.C. Wainwright

HC Wainwright & Co. Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $56

Target:$56.00

+33.5%from $41.96

Nov 22, 2022RBC Capital

RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54

Target:$54.00

+16.4%from $46.40

Jul 29, 2022Piper Sandler

Enanta's 'strong' EDP-235 data supports 'impressive' profile, says Piper Sandler

Target:$87.00

+69.7%from $51.27

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance